Skip to content

School Inner-City Asthma Intervention Study (SICAS-2)

School Inner-City Asthma Intervention Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02291302
Acronym
SICAS-2
Enrollment
236
Registered
2014-11-14
Start date
2015-01-31
Completion date
2020-06-30
Last updated
2025-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Brief summary

The investigators goal is to determine the efficacy of school/classroom based environmental intervention in reducing asthma morbidity in urban schoolchildren.

Detailed description

Our proposal builds upon our established, successful school-based infrastructure to determine whether a school/classroom intervention will efficiently and effectively improve asthma morbidity by reducing these exposures. Our goal is to determine the efficacy of school/classroom based environmental intervention in reducing asthma morbidity in urban schoolchildren. Our central hypothesis is that reducing classroom/school exposure to mouse allergen, mold, and particulate pollutants will decrease asthma morbidity in students with asthma. The investigators plan to test this hypothesis in an intervention study of 300 elementary students with asthma from multiple classrooms in inner-city elementary schools. Our clinical trial aims are to determine the effectiveness of a school/classroom based environmental intervention (school integrated pest management and classroom air purifying filter units within these schools) to reduce asthma morbidity. Our mechanistic aim is to test the hypothesis that effects of school/classroom-based environmental interventions on symptoms/other measures of asthma control occur through changes in gene methylation or expression in pathways (and secondarily, in genes) relevant to airway function and asthma. This will expand our understanding of asthma immunopathogenesis and create opportunities to identify potential novel targets for asthma therapy.

Interventions

integrated pest management and environmental strategy

air purifiers

no integrated pest management and sham air purifier

Sponsors

National Institutes of Health (NIH)
CollaboratorNIH
National Institute of Allergy and Infectious Diseases (NIAID)
CollaboratorNIH
Harvard School of Public Health (HSPH)
CollaboratorOTHER
Boston Children's Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
4 Years to 15 Years
Healthy volunteers
Yes

Inclusion criteria

* grades K-8 with asthma attending sampling/intervention schools

Exclusion criteria

* moving schools

Design outcomes

Primary

MeasureTime frameDescription
Maximum Number of Days With Asthma Symptoms Within 2 Weeksup to 12 monthsMaximum number of 1. Days with wheezing, tightness in the chest, or cough and/or 2. Nights with disturbed sleep as a result of asthma and/or 3. Days on which the child had to slow down or discontinue play activities because of asthma This is defined as a cumulative assessment from the different variables listed in the Measure Description

Other

MeasureTime frameDescription
Lung Function12 monthsSpirometry measure of forced expiration volume in 1 second
School Absences12 monthsNumber of school days missed because of asthma/ 2 weeks
Composite Asthma Severity Index12 months\[a comprehensive severity scale of day symptoms and albuterol use, night symptoms and albuterol use, controller treatment, lung function measures, and exacerbations\], health care utilization, and pulmonary function testing (PFT's) including FEV1; FEV1/FVC, FEF25-75. CASI ranges from 0 (lowest) -20 points (highest) with a minimal clinically important difference of 0.49 points. The higher score is worse outcome.

Countries

United States

Participant flow

Participants by arm

ArmCount
Environmental Intervention
Active Classroom air purifiers and school integrated pest management environmental intervention integrated pest management: integrated pest management and environmental strategy air purifier: air purifiers
59
Sham and Control (Control)
Sham air purifiers and no school integrated pest management environmental intervention No intervention (control): no integrated pest management and sham air purifier
59
Active Air Purifier and Control
Active air purifiers and no school integrated pest management environmental intervention air purifier: air purifiers
59
Sham and Inegrated Pest
Sham air purifiers and active school integrated pest management integrated pest management: integrated pest management and environmental strategy
59
Total236

Baseline characteristics

CharacteristicActive Air Purifier and ControlTotalSham and Inegrated PestEnvironmental InterventionSham and Control (Control)
Age, Customized
Age
8.3 years
STANDARD_DEVIATION 2.2
8.1 years
STANDARD_DEVIATION 2
8.2 years
STANDARD_DEVIATION 2
8.2 years
STANDARD_DEVIATION 1.9
7.9 years
STANDARD_DEVIATION 1.9
Ethnicity (NIH/OMB)
Hispanic or Latino
32 Participants138 Participants33 Participants38 Participants35 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
25 Participants93 Participants26 Participants21 Participants21 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
2 Participants5 Participants0 Participants0 Participants3 Participants
Maximum Number of Days With Asthma Symptoms Within 2 Weeks1.5 days
STANDARD_DEVIATION 3.4
2.2 days
STANDARD_DEVIATION 3.9
2.4 days
STANDARD_DEVIATION 4.2
2.0 days
STANDARD_DEVIATION 3.2
3.0 days
STANDARD_DEVIATION 4.7
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants1 Participants0 Participants1 Participants0 Participants
Race (NIH/OMB)
Asian
1 Participants6 Participants2 Participants2 Participants1 Participants
Race (NIH/OMB)
Black or African American
15 Participants57 Participants13 Participants17 Participants12 Participants
Race (NIH/OMB)
More than one race
8 Participants17 Participants6 Participants1 Participants2 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
15 Participants55 Participants12 Participants17 Participants11 Participants
Race (NIH/OMB)
White
20 Participants100 Participants26 Participants21 Participants33 Participants
Region of Enrollment
United States
59 participants236 participants59 participants59 participants59 participants
Sex: Female, Male
Female
32 Participants113 Participants33 Participants26 Participants22 Participants
Sex: Female, Male
Male
27 Participants123 Participants26 Participants33 Participants37 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
deaths
Total, all-cause mortality
0 / 590 / 590 / 590 / 59
other
Total, other adverse events
0 / 590 / 590 / 590 / 59
serious
Total, serious adverse events
0 / 590 / 590 / 590 / 59

Outcome results

Primary

Maximum Number of Days With Asthma Symptoms Within 2 Weeks

Maximum number of 1. Days with wheezing, tightness in the chest, or cough and/or 2. Nights with disturbed sleep as a result of asthma and/or 3. Days on which the child had to slow down or discontinue play activities because of asthma This is defined as a cumulative assessment from the different variables listed in the Measure Description

Time frame: up to 12 months

ArmMeasureValue (MEAN)Dispersion
Environmental InterventionMaximum Number of Days With Asthma Symptoms Within 2 Weeks2.2 daysStandard Deviation 3.5
Sham and Control (Control)Maximum Number of Days With Asthma Symptoms Within 2 Weeks2.7 daysStandard Deviation 4.4
Active Air Purifier and ControlMaximum Number of Days With Asthma Symptoms Within 2 Weeks1.2 daysStandard Deviation 2
Sham and Inegrated PestMaximum Number of Days With Asthma Symptoms Within 2 Weeks2.1 daysStandard Deviation 3.6
Post Hoc

Classroom Microbiome

The classroom microbiome will be assessed with deep metagenomics sequencing

Time frame: 1 year

Post Hoc

Classroom Viral Exposure

Classroom viral exposure will be assessed using two approaches: 1. Airborne respiratory viral exposure (copies/m3) 2. School viral exposure (assessed with virome sequencing)

Time frame: 1 year

Other Pre-specified

Composite Asthma Severity Index

\[a comprehensive severity scale of day symptoms and albuterol use, night symptoms and albuterol use, controller treatment, lung function measures, and exacerbations\], health care utilization, and pulmonary function testing (PFT's) including FEV1; FEV1/FVC, FEF25-75. CASI ranges from 0 (lowest) -20 points (highest) with a minimal clinically important difference of 0.49 points. The higher score is worse outcome.

Time frame: 12 months

ArmMeasureValue (MEAN)Dispersion
Environmental InterventionComposite Asthma Severity Index2.9 score on a scaleStandard Deviation 2.2
Sham and Control (Control)Composite Asthma Severity Index2.8 score on a scaleStandard Deviation 2.4
Active Air Purifier and ControlComposite Asthma Severity Index3.1 score on a scaleStandard Deviation 2.5
Sham and Inegrated PestComposite Asthma Severity Index2.9 score on a scaleStandard Deviation 2.2
Other Pre-specified

Lung Function

Spirometry measure of forced expiration volume in 1 second

Time frame: 12 months

ArmMeasureValue (MEAN)Dispersion
Environmental InterventionLung Function95.5 percentage of predictedStandard Deviation 18.5
Sham and Control (Control)Lung Function99.2 percentage of predictedStandard Deviation 16.9
Active Air Purifier and ControlLung Function97 percentage of predictedStandard Deviation 14.1
Sham and Inegrated PestLung Function94.9 percentage of predictedStandard Deviation 16.1
Other Pre-specified

School Absences

Number of school days missed because of asthma/ 2 weeks

Time frame: 12 months

ArmMeasureValue (MEAN)Dispersion
Environmental InterventionSchool Absences0.15 days/2 weeksStandard Deviation 0.61
Sham and Control (Control)School Absences0.18 days/2 weeksStandard Deviation 0.75
Active Air Purifier and ControlSchool Absences0.16 days/2 weeksStandard Deviation 0.74
Sham and Inegrated PestSchool Absences0.07 days/2 weeksStandard Deviation 0.33

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026